Zerbaxa: adverse event reports filed with FDA

891

reports as suspect product

0% of all reports · about 79 a year

18

reports, 12 months to June 2026

61 in the 12 months before

66.1%

marked serious by the reporter

89.1% across the class

21.9%

record death among outcomes, as reported

195 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Zerbaxa reports recording the termmedian drug in cephalosporin antibacterial

1. Off label useused for a purpose or in a way not on the label15%134
2. Product use in unapproved indicationused for a purpose not on the label14%125
3. No adverse eventno adverse event was reported9.8%87
4. Deaththe patient died; cause not stated by this term8.6%77
5. Product use issuea problem in how the product was used7.5%67
6. Pathogen resistance5.8%52
7. Drug ineffectivethe medicine did not work as expected4.6%41
8. Drug resistance2.9%26
9. Incorrect dose administeredthe wrong dose was given2.6%23
10. Acute kidney injurysudden loss of kidney function2.5%22
11. Pancytopenialow counts of all blood cells2.5%22
12. Adverse eventan unwanted medical event, type not specified2.2%20
13. Septic shockshock arising from infection2%18
14. Renal failurekidney failure1.9%17
15. Confusional stateconfusion1.8%16
16. Encephalopathy1.8%16
17. Thrombocytopenialow platelets1.8%16
18. Amnesiamemory loss1.7%15
19. Condition aggravatedthe condition being treated got worse1.7%15
20. Overdosea dose above the recommended amount1.7%15
21. Pneumonia pseudomonal1.7%15
22. Agranulocytosis1.6%14
23. Erythemaskin redness1.5%13
24. Product storage errorthe product was stored wrongly1.5%13
25. Pseudomonas infection1.5%13
26. Seizurea fit or convulsion1.5%13
27. Treatment failurethe treatment did not work1.3%12
28. Respiratory failurethe lungs could not supply enough oxygen1.2%11
29. Sepsisa severe body-wide response to infection1.2%11
30. Drug interactionan interaction between medicines1.1%10

Top 30 of 135 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 17 drugs in the cephalosporin antibacterial class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 57,006 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 47.8% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 891 reports.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the cephalosporin antibacterial class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Zerbaxa as a suspect or interacting product; reports listing it only as a concomitant medication (74) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.